Raise closed, search for fresh raises on Seedstage

Scottsdale, AZ

Developing non-thermal plasma technology for antibiotic-resistant wound treatment.

• Mission: Developing Plaz4® Technology to offer drug-free, painless treatments for antibiotic-resistant wounds and other medical needs, addressing global healthcare challenges.  
• Innovation: Leveraging non-thermal plasma to provide a novel, effective solution for treating multidrug-resistant wounds, with promising results in laboratory studies.  
• Market Opportunity: Targeting the $50 billion+ wound care and infection control markets, with potential for expansion into other medical sectors.  
• Funding Uses: Advancing commercial development and regulatory approval, including FDA clearance for the Plaz4® 1000, anticipated in 2026.  
• Healthcare Impact: Offering a potential breakthrough in chronic wound and infection treatment, combating the global health threat of antibiotic resistance.  
• Strategic Positioning: Backed by 45 patents and substantial funding, Plasmology4 is poised to transform wound care with its proprietary plasma-based technology.

Plasmology4 is pioneering the use of non-thermal plasma, known as Plaz4® Technology, to address antibiotic-resistant wounds and other medical needs in healthcare. Their anticipated first product, the Plaz4® 1000, aims to treat multidrug-resistant wounds and is currently under FDA’s Breakthrough Devices Program, with an expected market clearance goal for 2026. Plaz4® Technology is designed to provide a drug-free, painless solution, demonstrating promise in laboratory settings for pathogen elimination and wound healing.

Backed by a substantial patent portfolio and over $48 million in funding, Plasmology4 is advancing towards commercial development in a field with significant healthcare impact. The company is targeting the wound care and infection control markets, estimated to exceed $50 billion, with potential future applications across other medical sectors. Plasmology4’s efforts could provide new therapeutic options for chronic wounds and help mitigate global health challenges posed by antibiotic resistance.

Company Info

Plasmology4 is developing Plaz4® Technology, a non-thermal plasma solution for treating multidrug-resistant infections and chronic wounds.

Plasmology4 is advancing healthcare technology with its proprietary Plaz4® Technology, a specialized form of non-thermal plasma. Aiming to address the increasing challenges of multidrug-resistant infections and chronic wounds, their first product, the Plaz4® 1000, is focused on providing a drug-free, painless wound care solution. Already part of the FDA’s Breakthrough Devices Program, Plasmology4 anticipates moving toward market clearance in 2026. Backed by 45 patents and $48M in funding, the company is developing this technology as a potential transformative option in wound care and infection control.

Plasmology4’s approach leverages plasma medicine to disrupt traditional treatment models, targeting a $50B+ wound care market and addressing significant global health concerns related to antibiotic resistance. As the company remains in the pre-revenue phase, it is focused on refining its technology and navigating the regulatory pathway to bring Plaz4® to patients worldwide.